1. 1) Smolen, J.S., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Mar 6. pii: annrheumdis-2016-210715.
2. 2) Baecklund, E., et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54: 692-701, 2006.
3. 3) Ellman, M.H., et al.: Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 18: 1741-1743, 1991.
4. 4) Gaulard, P., et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow, S.H., Campo, E., Harris, N.L., et al (eds). IARC Press; 2008: 350-351.
5. 5) Kameda, T., et al.: Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 66: 1302-1309, 2014.